HEPA Hepion Pharmaceuticals Inc.: יחס שווי שוק לשווי בספרים

Hepion Pharmaceuticals (HEPA) utilizes AI platforms to automate the analysis of clinical tests. The company's price-to-book ratio demonstrates high market sensitivity, where 0.25 determines this parameter level. While the biotech's strategy targets long-term liver therapy, primary trials have been halted due to a liquidity shortage, and the company is currently seeking survival options.

Hepion Pharmaceuticals focuses on developing innovative therapies for liver cirrhosis and fibrosis. The market value dynamics of these developments relative to net assets determine the current market value to book value ratio. This metric compares the exchange valuation with the balance sheet value, identifying whether the business is overbought or undervalued. Low values may signal a value trap if asset quality deteriorates. Analysis of this chart allows for an assessment of the real fundamental stability of the biopharmaceutical startup.